FYI ... Nivolumab was my Clinical Trial therapy in 2014😲🤔👍💪

[GCCA-Survivor]

The U.S. FDA has approved nivolumqb plus ipilimumab for dMMR / MSI-H metastatic colorectal cancer. GCCA President, Nicole Sheahan, commented, “Colorectal cancer is the third most commonly diagnosed cancer and the second most common cause of cancer-related death for men and women combined in the U.S., and concerning trends show that incidence is increasing in people younger than 50. Despite the prevalence of CRC, there remains a high unmet need, highlighting the urgency for additional treatment options. We are thrilled with this FDA approval as Opdivo plus Yervoy offers an exciting new first-line approach for patients with MSI-H/dMMR metastatic colorectal cancer.

l.facebook.com/l.php?u=http...

[GCCA-Survivor Administrator]

Nivolumab was an approved therapy for certain lung and melanoma cancer patients. It was interesting as I had stage 4 colon cancer. Genetic testing showed I had a lot in common with the lung and melanoma patients being MSI-h. I did the genetic testing 2 years prior to being invited to the clinical trial.👍